# Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

> **NCT00091078** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 96 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00091078
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091078, "Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00091078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*